Following publication of the Research Article by Stephan J Matissek, Weiguo Han, Mona Karbalivand, Mohamed Sayed, Brendan M Reilly, Shayna Mallat, Shimaa M Ghazal, Manit Munshi, Guang Yang, Steven P Treon, Sarah R Walker & Sherine F Elsawa, titled ‘Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition’, which appeared in the January 2021 issue of Epigenomics (Epigenomics 13(2):129–144 (2021) doi:10.2217/epi-2020-0189), it has been brought to our attention that the article was published with typographical errors affecting the details of drug concentrations in the manuscript by ‘μ’ being incorrectly written as ‘m’. These errors were highlighted by the authors, who have explained this arose when revising the article, transferring the manuscript text between operating systems. There was no effect of these errors on the overall results and conclusion as the research was conducted and the manuscript peer-reviewed with the correct concentrations.
In the Results, subsection ‘BET inhibition reduces growth of WM cells’, there were errors in the following sentences: “WM cells were treated with different concentrations (0.5, 1 and 5 mM) of either iBET (Figure 1A) or JQ1 (Figure 1B) for 72 h. We found a significant reduction in cell proliferation in all three cell lines, starting with the lowest dose of 0.5 mM for both iBET (p < 0.0001) and JQ-1 (p < 0.0001). While a dose dependent effect was visible for both drugs in all three cell lines, JQ1 showed the strongest inhibitory effect on cell proliferation; approximately 70 percent reduction in cell proliferation was achieved at the highest dose (p < 0.0001). We investigated the effect of BET inhibition on cell cycle and found that iBET and JQ1 induced cell cycle arrest at G0/G1 phase (Figure 1C). Between both compounds used, JQ1 showed the stronger anti-proliferative effect, at both lower (0.5 mM) and higher doses (5 mM) (Figure 1)”, which have now been corrected to: “WM cells were treated with different concentrations (0.5, 1 and 5 μM) of either iBET (Figure 1A) or JQ1 (Figure 1B) for 72 h. We found a significant reduction in cell proliferation in all three cell lines, starting with the lowest dose of 0.5 μM for both iBET (p < 0.0001) and JQ1 (p < 0.0001). While a dose dependent effect was visible for both drugs in all three cell lines, JQ1 showed the strongest inhibitory effect on cell proliferation; approximately 70 percent reduction in cell proliferation was achieved at the highest dose (p < 0.0001). We investigated the effect of BET inhibition on cell cycle and found that iBET and JQ1 induced cell cycle arrest at G0/G1 phase (Figure 1C). Between both compounds used, JQ1 showed the stronger anti-proliferative effect, at both lower (0.5 μM) and higher doses (5 μM) (Figure 1).”
In the first paragraph of the Results subsection “Combined treatment with BET inhibitors synergizes with HDAC and BCL2 but not BTK inhibition in WM” there were errors in the following sentence: “Therefore, we treated WM cells with either 5 mM JQ1, 5 mM Venetoclax (ABT-199) or a combination of both and examined the effect on WM cell survival.” This has now been corrected to: “Therefore, we treated WM cells with either 5 μM JQ1, 5 mM Venetoclax (ABT-199) or a combination of both and examined the effect on WM cell survival.” In the second paragraph of the same section, there was an error in the following sentence: “Cells were treated with either 5 mM JQ1 or 25 nM Panobinostat (LBH589) alone or a combination of both and examined for the effect on WM cell survival.” This has now been corrected to: “Cells were treated with either 5 μM JQ1 or 25 nM Panobinostat (LBH589) alone or a combination of both and examined for the effect on WM cell survival.” In the third paragraph of the same section, there were errors in the following sentence: “To examine the role of Ibrutinib in combination with BET inhibition, we treated WM cells with either 5 mM JQ1, 5 mM Ibrutinib or a combination of both and examined the effect on WM cell survival”, which has now been corrected to: “To examine the role of Ibrutinib in combination with BET inhibition, we treated WM cells with either 5 μM JQ1, 5 μM Ibrutinib or a combination of both and examined the effect on WM cell survival.”
In the final paragraph of the Discussion, there was an error in the following sentence: “Although Ibrutinib has shown efficacy in WM patients [38], at 5 mM, there was no effect on cell survival and a limited effect on cell proliferation; RPCI-WM1 cells were the most resistant to Ibrutinib (Fig 7)”, which has now been corrected to: “Although Ibrutinib has shown efficacy in WM patients [38], at 5 μM, there was no effect on cell survival and a limited effect on cell proliferation; RPCI-WM1 cells were the most resistant to Ibrutinib (Fig 7).”
In the legend for Figure 1, there was an error in the following sentence: “Bars represent the mean ± SE of at least 3 biological replicates of each experiment. (C) WM cells (0.5 × 106) were treated with 5 mM I-BET, JQ1 or DMSO control for 72 hours followed by cell cycle analysis as described in the methods”, which has now been corrected to: “Bars represent the mean ± SE of at least 3 biological replicates of each experiment. (C) WM cells (0.5 × 106) were treated with 5 μM I-BET, JQ1 or DMSO control for 72 hours followed by cell cycle analysis as described in the methods.”
In the legend for Figure 2 (B), there was an error in the following sentence: “WM cells (0.5 × 103) were added to each well and treated with either 5 mM of iBET, JQ1, or DMSO control”, which has now been corrected to: “WM cells (0.5 × 103) were added to each well and treated with either 5 μM of iBET, JQ1, or DMSO control.” In the legend for Figure 2 (C), there was an error in the following sentence: “HS-5 cells (0.25 × 103) were treated with 5 mM iBET, 5 mM JQ1 or DMSO control for 72 hours, followed by the determination of cell proliferation using an XTT assay.”, which has now been corrected to: “HS-5 cells (0.25 × 103) were treated with 5 μM iBET, 5 μM JQ1 or DMSO control for 72 hours, followed by the determination of cell proliferation using an XTT assay.”
In the legend for Figure 3, there was an error in the following sentence: “WM cells (0.5 × 106) were treated with 5 mM of I-BET or JQ1, or DMSO control for 72 hours”, which has now been corrected to: “WM cells (0.5 × 106) were treated with 5 μM of I-BET or JQ1, or DMSO control for 72 hours.”
In the legend for Figure 4 (A), there was an error in the following sentence: “WM cells (2 × 106) were treated with 5 mM of either iBET or JQ1 or DMSO control for 24 hours”, which has now been corrected to: “WM cells (2 × 106) were treated with 5 μM of either iBET or JQ1 or DMSO control for 24 hours”. In the legend for Figure 4 (B), there was an error in the following sentence: “WM cells (5 × 106) were treated with either 5 mM of iBET, JQ1 or DMSO control for 24 hours”, which has now been corrected to: “WM cells (5 × 106) were treated with either 5 μM of iBET, JQ1 or DMSO control for 24 hours.” In the legend for Figure 4 (C), there was an error in the following sentence: “WM cells (5 × 106) were treated with either 5 mM of iBET, JQ1 or DMSO control for 24 hours”, which has now been corrected to: “WM cells (5 × 106) were treated with either 5 μM of iBET, JQ1 or DMSO control for 24 hours.”
In the legend for Figure 5 (A), there was an error in the following sentence: “WM cells (2 × 106) were treated with 5 mM of iBET or DMSO control for 24 hours”, which has now been corrected to: “WM cells (2 × 106) were treated with 5 μM of iBET or DMSO control for 24 hours.” In the legend for Figure 5 (B), there was an error in the following sentence: “WM cells (2 × 106) were treated with either 5 mM iBET or DMSO control for 72 hr”, which has been corrected to: “WM cells (2 × 106) were treated with either 5 μM iBET or DMSO control for 72 hr.”
In the legend for Figure 6 (A) & (B), there was an error in the following sentence: “WM cells (0.5 × 106) were treated with either 500 nM of ABT-199, 5 mM of JQ1, a combination of Venetoclax (ABT-199) and JQ1, or DMSO control for 72 hours”, which has now been corrected to: “WM cells (0.5 × 106) were treated with either 500 nM of ABT-199, 5 μM of JQ1, a combination of Venetoclax (ABT-199) and JQ1, or DMSO control for 72 hours.” In the legend for Figure 6 (C) & (D), there was an error in the following sentence: “WM cells (0.5 × 106) were treated with either 25 nM of Panobinostat (LBH589), 5 mM of JQ1, a combination of LBH589 and JQ1, or DMSO control for 72 hours”, which has now been corrected to: “WM cells (0.5 × 106) were treated with either 25 nM of Panobinostat (LBH589), 5 μM of JQ1, a combination of LBH589 and JQ1, or DMSO control for 72 hours.”
In the legend for Figure 7 (A), there was an error in the following sentence: “WM cells (0.5 × 106) were treated with either 5 mM of Ibrutinib, 5 mM of JQ1, combination of Ibrutinib and JQ1, or DMSO control for 72 hours, followed by determination of cell viability by Annexin-V/PI double staining”, which has now been corrected to: “WM cells (0.5 × 106) were treated with either 5 μM of Ibrutinib, 5 μM of JQ1, combination of Ibrutinib and JQ1, or DMSO control for 72 hours, followed by determination of cell viability by Annexin-V/PI double staining.” In the legend for Figure 7 (B), there was an error in the following sentence: “WM cells (0.25 × 103) were treated with either 5 mM of Ibrutinib, 5 mM of JQ1, combination of Ibrutinib and JQ1, or DMSO control for 72 hours, followed by the determination of cell proliferation using an XTT assay as described in methods”, which has now been corrected to: “WM cells (0.25 × 103) were treated with either 5 μM of Ibrutinib, 5 μM of JQ1, combination of Ibrutinib and JQ1, or DMSO control for 72 hours, followed by the determination of cell proliferation using an XTT assay as described in methods.”
The authors and editors of Epigenomics would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.